Ignite Creation Date:
2024-05-06 @ 5:49 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05446428
Status:
UNKNOWN
Last Update Posted:
2022-07-06
First Post:
2022-06-30
Brief Title:
Evaluation of Type I IFN Level and Disease Activity in SLE Patients
Sponsor:
VA Nasonova Research Institute of Rheumatology Moscow
Organization:
VA Nasonova Research Institute of Rheumatology Moscow
Study Overview
Official Title:
Evaluation of Type I IFN Level and Disease Activity in SLE Patients
Status:
UNKNOWN
Status Verified Date:
2022-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Elevated level of IFN type I in SLE patients associated with certain serum biomarkers galectin -1-3-9 cytokine profile - 20 plex panel - GM-CSF IFN-γ IL-2 -4-5-6-7-8-10-13-15-17-18 IP-10 MCP-1 MIG MIP-1α MIP-1β RANTES TNF-α TNF-RII BAFF APRIL clinical and laboratory manifestations activity and duration pf the disease and SLE patients quality of life Standard immunosuppressive and anti-B-cell therapy can reduce the IFN type I and associated biomarkers levels in patients with high and moderate disease activity SLEDAI-2К 6
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None